


CLAIMS

1. A compound of formula (I)



(I)

or a pharmaceutically acceptable salt or stereoisomer thereof; wherein

A is an optionally substituted heteroaryl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, optionally substituted cycloalkyl-NR_x-, optionally substituted heterocycloalkyl-NR_x-, optionally substituted aryl-NR_x-, optionally substituted heteroaryl-NR_x-, optionally substituted cycloalkyl-O-, optionally substituted heterocycloalkyl-O-, optionally substituted aryl-O- or optionally substituted heteroaryl-O-; e.g., wherein each optional substituent independently represents an occurrence of R_z;

B is hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, -NR_aR_b, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, optionally substituted cycloalkyl-NR_x-, optionally substituted heterocycloalkyl-NR_x-, optionally substituted aryl-NR_x-, optionally substituted heteroaryl-NR_x-, optionally substituted cycloalkyl-O-, optionally substituted heterocycloalkyl-O-, optionally substituted aryl-O-, optionally substituted heteroaryl-O-; e.g., wherein each optional substituent independently represents an occurrence of R_y;

Q is absent, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted (heteroaryl)alkyl, optionally substituted

aralkyl, optionally substituted (cycloalkyl)alkyl, -NR₃R₄, -O-R₃ or -S-R₃; e.g., wherein each optional substituent independently represents an occurrence of R_z;

W is N or CH;

R₁ is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted heterocycloalkyl, optionally substituted aralkyl, optionally substituted (heteroaryl)alkyl-, optionally substituted alkoxyalkyl, optionally substituted aminoalkyl, or -(CH₂)_m-R₂; e.g., wherein each optional substituent independently represents halo, hydroxy, alkoxy, amino, nitro, cycloalkyl, aryl, heterocycloalkyl or heteroaryl;

R₂ is hydrogen, -NR_aR_b, alkoxy, hydroxy, optionally substituted heteroaryl or optionally substituted heterocycloalkyl; e.g., wherein each optional substituent independently represents an occurrence of R_y;

each R₃ and R₄ is independently selected from optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted aralkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heteroaryl)alkyl and optionally substituted (heterocycloalkyl)alkyl; e.g., wherein each optional substituent is independently selected from alkyl, halo, haloalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, amino, nitro, cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heteroaryl and (heteroaryl)alkyl;


each R_a and R_b is independently selected from hydrogen, alkyl, aminoalkyl, acyl and heterocyclyl; or R_a and R_b are taken together with the nitrogen to which they are attached to form an optionally substituted ring;

R_x is hydrogen, alkyl, hydroxy, hydroxyalkyl, acyl or cycloalkyl;

each R_y and R_z is independently selected from hydroxy, hydroxyalkyl, halo, alkyl, oxo, haloalkyl, alkoxy, alkenyloxy, amino, nitro, cyano, -SH, -S(alkyl), glycinate, ester, thioester, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, aralkyl, and (heteroaryl)alkyl; optionally wherein the hydroxy, hydroxyalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are further substituted by one or more substituents selected from alkyl, halo, alkenyl, amino, nitro, cycloalkyl and (cycloalkyl)alkyl; or

R_y and R_z taken together with the atoms to which they are attached form an alkyl chain having 1-10 carbon atoms; optionally wherein 1-3 carbon atoms are replaced by O, NH or S;
 m is 1, 2, or 3; and
 n is 1 or 2.

2. A compound of formula (II)



or a pharmaceutically acceptable salt or stereoisomer thereof; wherein

A is an optionally substituted heteroaryl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, optionally substituted cycloalkyl-NR_x-, optionally substituted heterocycloalkyl-NR_x-, optionally substituted aryl-NR_x-, optionally substituted heteroaryl-NR_x-, optionally substituted cycloalkyl-O-, optionally substituted heterocycloalkyl-O-, optionally substituted aryl-O- or optionally substituted heteroaryl-O-; e.g., wherein each optional substituent independently represents an occurrence of R_z ;

B is hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, -NR_aR_b, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, optionally substituted cycloalkyl-NR_x-, optionally substituted heterocycloalkyl-NR_x-, optionally substituted aryl-NR_x-, optionally substituted heteroaryl-NR_x-, optionally substituted cycloalkyl-O-, optionally substituted heterocycloalkyl-O-, optionally substituted aryl-O-, optionally substituted heteroaryl-O-; e.g., wherein each optional substituent independently represents an occurrence of R_y ;

Q is absent, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted (heteroaryl)alkyl, optionally substituted aralkyl, optionally substituted (cycloalkyl)alkyl, -NR₃R₄, -O-R₃ or -S-R₃; e.g., wherein each optional substituent independently represents an occurrence of R_z;

W is N or CH;

R₁ is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted heterocycloalkyl, optionally substituted aralkyl, optionally substituted (heteroaryl)alkyl-, optionally substituted alkoxyalkyl, optionally substituted aminoalkyl, or -(CH₂)_m-R₂; e.g., wherein each optional substituent independently represents one or more substituents selected from halo, hydroxy, alkoxy, amino, nitro, cycloalkyl, aryl, heterocycloalkyl and heteroaryl;

R₂ is hydrogen, -NR_aR_b, alkoxy, hydroxy, optionally substituted heteroaryl or optionally substituted heterocycloalkyl; e.g., wherein each optional substituent independently represents an occurrence of R_y;

each R₃ and R₄ is independently selected from optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, optionally substituted aralkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heteroaryl)alkyl and optionally substituted (heterocycloalkyl)alkyl; e.g., wherein each optional substituent independently represents one or more substituents selected from alkyl, halo, haloalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, amino, nitro, cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heteroaryl and (heteroaryl)alkyl;

each R_a and R_b is independently selected from hydrogen, alkyl, aminoalkyl, acyl and heterocyclyl; or R_a and R_b are taken together with the nitrogen to which they are attached to form an optionally substituted ring;

R_x is hydrogen, alkyl, hydroxy, hydroxyalkyl, acyl or cycloalkyl;

each R_y and R_z is independently selected from hydroxy, hydroxyalkyl, halo, alkyl, oxo, haloalkyl, alkoxy, alkenyloxy, amino, nitro, cyano, -SH, -S(alkyl), glycinate, ester,

thioester, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, aralkyl, and (heteroaryl)alkyl; optionally wherein the hydroxy, hydroxyalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are further substituted by one or more substituents selected from alkyl, halo, alkenyl, amino, nitro, cycloalkyl and (cycloalkyl)alkyl; or R_y and R_z taken together with the atoms to which they are attached form an alkyl chain having 1-10 carbon atoms; optionally wherein 1-3 carbon atoms are replaced by O, NH or S;

m is 1, 2, or 3; and

n is 1 or 2.

3. The compound of claim 1 or 2, wherein A is an optionally substituted heteroaryl, optionally substituted aryl, optionally substituted heterocycloalkyl or optionally substituted cycloalkyl.

4. The compound of any one of claims 1 to 3, wherein A is an optionally substituted heteroaryl or optionally substituted heterocycloalkyl; wherein each optional substituent independently represents an occurrence of R_z .

5. The compound of claim 3, wherein A is optionally substituted heteroaryl; wherein each optional substituent independently represents an occurrence of R_z .

6. The compound of any one of claims 1 to 5, wherein A is substituted and each substituent independently represents an occurrence of R_z .

7. The compound of any one of claims 1 to 6, wherein B is hydrogen, halogen, cyano, optionally substituted alkyl, alkoxy, $-NR_aR_b$, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted aralkyl or optionally substituted heteroaralkyl.

8. The compound of claim 7, wherein B is $-NR_aR_b$, optionally substituted heteroaryl or optionally substituted heterocycloalkyl; wherein each optional substituent is an occurrence of R_y .
9. The compound of any one of claims 1 to 8, wherein B is substituted, and each substituent independently represents an occurrence of R_y .
10. The compound of any one of claims 1 to 9, wherein Q is absent, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted aryl, or optionally substituted cycloalkyl.
11. The compound of any one of claims 1 to 10, wherein Q is absent.
12. The compound of any one of claims 1 to 10, wherein Q is an optionally substituted heteroaryl or optionally substituted heterocycloalkyl, wherein each optional substituent independently represents one or more R_z .
13. The compound of any one of claims 1 to 10, wherein Q is substituted, and each substituent independently represents an occurrence of R_z .
14. The compound of any one of claims 1 to 13, wherein R_1 is optionally a substituted heterocycloalkyl or $-(CH_2)_m-R_2$.
15. The compound of any one of claims 1 to 14, wherein R_1 is substituted and each substituent independently represents halo, hydroxy, alkoxy, amino, nitro, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl.
16. The compound of any one of claims 1 to 15, wherein R_2 is $-NR_aR_b$, alkoxy, hydroxy, heteroaryl or heterocycloalkyl, and each R_a and R_b is independently hydrogen or alkyl.
17. The compound of any one of claims 1 to 16, wherein R_2 is substituted, each substituent independently represents an occurrence of R_y .

A is an optionally substituted heteroaryl, optionally substituted aryl, optionally substituted heterocycloalkyl or optionally substituted cycloalkyl;

B is hydrogen, halogen, cyano, optionally substituted alkyl, alkoxy, -NR_aR_b, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted aralkyl or optionally substituted heteroaralkyl;


Q is absent, is optionally substituted heterocycloalkyl, optionally substituted heteroaryl, optionally substituted aryl or optionally substituted cycloalkyl;

R₁ is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkyl, optionally substituted (heterocycloalkyl)alkyl, optionally substituted heterocycloalkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, optionally substituted alkoxyalkyl, optionally substituted aminoalkyl, or $-(CH_2)_m-R_2$;

R_a and R_b, independently for each occurrence, are hydrogen, alkyl, aminoalkyl, acyl or heterocyclyl;

n is 1 or 2.


114



(IA)

or a pharmaceutically acceptable salt or stereoisomer thereof.


20. The compound of any one of claims 1-18 having the structure of formula (IB):



(IB)

or a pharmaceutically acceptable salt or stereoisomer thereof.


21. The compound of any one of claims 1-18, having the structure of formula (IC):



(IC)

or a pharmaceutically acceptable salt or stereoisomer thereof.


22. The compound of any one of claims 2-18, having the structure of formula (IIA):



(IIA)


or a pharmaceutically acceptable salt or stereoisomer thereof.

23. The compound of any one of claims 2-18, having the structure of formula (IIB):



or a pharmaceutically acceptable salt or stereoisomer thereof.

24. The compound of any one of claims 2-18, having the structure of formula (IIC):



or a pharmaceutically acceptable salt or stereoisomer thereof.

25. A compound selected from

Example	IUPAC Name
1	2-(2-aminopyridin-3-yl)-N-(6-(4-hydroxypiperidin-1-yl)-1-methyl-1H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;
2	N-(1-(2-(dimethylamino)ethyl)-6-(4-hydroxypiperidin-1-yl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
3	N-(6-(4-hydroxypiperidin-1-yl)-1-(2-morpholinoethyl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
4	N-(6-(4-hydroxypiperidin-1-yl)-1-(3-methoxypropyl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;
5	N-(6-(4-hydroxypiperidin-1-yl)-1-(3-morpholinopropyl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
6	N-(6-(4-hydroxypiperidin-1-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;

Example	IUPAC Name
7	2-(2-aminopyridin-4-yl)-N-(6-(4-hydroxypiperidin-1-yl)-1-(2-methoxyethyl)-1H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;
8	N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride;
9	2-(2-aminopyridin-4-yl)-N-(6-(4-hydroxypiperidin-1-yl)-1-(2-methoxyethyl)-3-methyl-1H-indazol-5-yl)oxazole-4-carboxamide;
10	2-(2-aminopyridin-4-yl)-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1-(2-methoxyethyl)-3-methyl-1H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;
11	2-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;
12	N-(6-(4-((allyloxy)methyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)-2-(2-aminopyridin-4-yl)oxazole-4-carboxamide;
13	N-(2-methyl-6-(piperidin-1-yl)-2H-pyrazolo[3,4-b]pyridin-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;
14	(S)-6-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-pyrazolo[3,4-b]pyridin-5-yl)picolinamide;
15	(S)-6-(3-aminopyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-pyrazolo[3,4-b]pyridin-5-yl)picolinamide;
16	N-(1-methyl-6-(piperidin-1-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
17	(S)-2-(3-aminopyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-pyrazolo[3,4-b]pyridin-5-yl)oxazole-4-carboxamide;
18	(S)-2-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-pyrazolo[3,4-b]pyridin-5-yl)oxazole-4-carboxamide;
19	(S)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-pyrazolo [3,4-b]pyridin-5-yl)picolinamide;
20	(S)-N-(6-(3-hydroxypyrrolidin-1-yl)-2-methyl-2H-pyrazolo[3,4-b]pyridin-

Example	IUPAC Name
	5-yl)-2-(3-methylpyridin-4-yl)oxazole-4-carboxamide;
21	(S)-N-(6-(3-hydroxypyrrolidin-1-yl)-2-methyl-2H-pyrazolo [3,4-b]pyridin-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
22	(S)-N-(6-cyclopropyl-2-methyl-2H-pyrazolo[3,4-b]pyridin-5-yl)-2-(3-hydroxypyrrolidin-1-yl)oxazole-4-carboxamide;
23	(S)-N-(6-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
24	2-(2-aminopyridin-4-yl)-N-(2,3-dimethyl-6-(piperidin-1-yl)-2H-pyrazolo[3,4-b]pyridin-5-yl)oxazole-4-carboxamide;
25	N-(6-(4-hydroxypiperidin-1-yl)-1-(2-methoxyethyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
26	N-(2,3-dimethyl-6-(piperidin-1-yl)-2H-pyrazolo[3,4-b]pyridin-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
27	2-(2-aminopyridin-4-yl)-N-(2,3-dimethyl-6-(piperidin-1-yl)-2H-pyrazolo[3,4-b]pyridin-5-yl)oxazole-4-carboxamide;
28	N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;
29	2-(2-aminopyridin-4-yl)-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-yl)oxazole-4-carboxamide;
30	2-(2-aminopyridin-4-yl)-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1-(2-methoxyethyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)oxazole-4-carboxamide;
31	2-(2-aminopyridin-4-yl)-N-(6-(4-hydroxypiperidin-1-yl)-1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-indazol-5-yl)oxazole-4-carboxamide; hydrochloride;
32	N-(6-cyclopropyl-1-(piperidin-4-yl)-1H-indazol-5-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide hydrochloride;
33	6-(3-hydroxypyrrolidin-1-yl)-N-(1-methyl-6-(piperidin-1-yl)-1H-indazol-5-yl)picolinamide;

Example	IUPAC Name
34	N-(6-(4-((allyloxy)methyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)-2-(6-aminopyridin-2-yl)oxazole-4-carboxamide;
35	2-(2-aminopyridin-4-yl)-N-(6-(4-(ethoxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)oxazole-4-carboxamide;
36	2-(2-aminopyridin-4-yl)-N-(6-(4-((cyclopropylmethoxy)methyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)oxazole-4-carboxamide;
37	6'-amino-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)-[2,3'-bipyridine]-6-carboxamide hydrochloride;
38	2-(2-amino-5-chloropyridin-4-yl)-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;
39	(Z)-51,53-dimethyl-51H-8-oxa-4,12-diaza-2(2,4)-oxazola-5(5,6)-indazola-1(4,2)-pyridina-6(1,4)-piperidinacyclododecaphan-3-one;
40	5-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-pyrazolo[3,4-b]pyridin-5-yl)picolinamide;
41	2-(6-aminopyridin-2-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)oxazole-4-carboxamide;
42	2-(6-aminopyridin-2-yl)-N-(2-methyl-6-(morpholin-1-yl)-2H-indazol-5-yl)oxazole-4-carboxamide;
43	2'-amino-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-[2,4'-bipyridine]-6-carboxamide hydrochloride;
44	6'-amino-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-[2,3'-bipyridine]-6-carboxamide;
45	2'-amino-3-methoxy-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-[2,4'-bipyridine]-6-carboxamide;
46	6'-amino-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-[2,2'-bipyridine]-6-carboxamide;
47	6-(2-aminopyrimidin-4-yl)-N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)picolinamide;

Example	IUPAC Name
48	6'-amino-N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)-[2,3'-bipyridine]-6-carboxamide;
49	6'-amino-N-(2-methyl-6-morpholino-2H-indazol-5-yl)-[2,3'-bipyridine]-6-carboxamide;
50	2'-amino-N-(2-methyl-6-morpholino-2H-indazol-5-yl)-[2,4'-bipyridine]-6-carboxamide hydrochloride;
51	6'-amino-N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)-[2,2'-bipyridine]-6-carboxamide hydrochloride;
52	2'-amino-N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)-[2,4'-bipyridine]-6-carboxamide;
53	6-amino-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-[3,4'-bipyridine]-2'-carboxamide hydrochloride;
54	N-(6-cyclopropyl-2-(piperidin-4-yl)-2H-indazol-5-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide hydrochloride;
55	N-(6-cyclopropyl-2-(2-morpholinoethyl)-2H-indazol-5-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide;
56	N-(6-cyclopropyl-2-(1-methylpiperidin-4-yl)-2H-indazol-5-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide hydrochloride;
57	(R)-6-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;
58	(R)-1-(6-((2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)carbamoyl)pyridin-2-yl)pyrrolidin-3-yl glycinate 2,2,2-trifluoroacetate;
59	6-(3-hydroxypyrrolidin-1-yl)-5-methyl-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;
60	6-(4-hydroxypiperidin-1-yl)-5-methyl-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;
61	6-(3-hydroxypyrrolidin-1-yl)-N-(2-(2-methoxyethyl)-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;

Example	IUPAC Name
62	6-(3-hydroxypyrrolidin-1-yl)-5-methoxy-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;
63	2-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)pyrimidine-4-carboxamide;
64	6-(3-hydroxypyrrolidin-1-yl)-N-(2-(2-morpholinoethyl)-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;
65	6-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)pyrazine-2-carboxamide;
66	N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)-6-(3-hydroxypyrrolidin-1-yl)pyrazine-2-carboxamide hydrochloride;
67	6-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)pyrazine-2-carboxamide hydrochloride;
68	6-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-morpholino-2H-indazol-5-yl)picolinamide;
69	4-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;
70	N-(2,6-dimethyl-2H-indazol-5-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide;
71	N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)-4-(3-hydroxypyrrolidin-1-yl)picolinamide hydrochloride;
72	N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)-2-(3-hydroxypyrrolidin-1-yl)pyrimidine-4-carboxamide; and
73	5-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

26. A pharmaceutical composition, comprising at least one compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt or a stereoisomer thereof, and a

pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient or a pharmaceutically acceptable diluent.

27. Use of a compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt or a stereoisomer thereof, in the manufacture of a medicament for the treatment of an IRAK-4-mediated disorder, disease or condition in a subject.

28. The use of claim 27, wherein the IRAK-4-mediated disorder or disease or condition is selected from cancer, an inflammatory disorder, an autoimmune disease, a metabolic disorder, a hereditary disorder, a hormone-related disease, an immunodeficiency disorder, a condition associated with cell death, a destructive bone disorder, thrombin-induced platelet aggregation, liver disease and a cardiovascular disorder.

29. The use of claim 28, wherein the cancer is selected from a solid tumor, benign or malignant tumor; carcinoma of the brain, kidney, liver, stomach, vagina, ovaries, gastric tumors, breast, bladder, colon, prostate, pancreas, lung, cervix, testis, skin, bone or thyroid; sarcoma, glioblastoma, neuroblastoma, gastrointestinal cancer, a tumor of the neck and head, an epidermal hyperproliferation, prostate hyperplasia, a neoplasia, adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, non-small-cell lung carcinoma, lymphomas, Hodgkins and Non-Hodgkins lymphoma, mammary carcinoma, follicular carcinoma, papillary carcinoma, seminoma, melanoma, haematological malignancies, leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), activated B-cell-like DLBCL, chronic lymphocytic leukemia (CLL), chronic lymphocytic lymphoma, primary effusion lymphoma, Burkitt's lymphoma, Burkitt's leukemia, acute lymphocytic leukemia, B-cell pro lymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's macroglobulinemia (WM), splenic marginal zone lymphoma, intravascular large B-cell lymphoma, plasmacytoma and multiple myeloma.

30. The use of claim 28, wherein the inflammatory disorder is selected from ocular allergy, conjunctivitis, keratoconjunctivitis sicca, vernal conjunctivitis, allergic rhinitis, autoimmune hematological disorders (e.g., hemolytic anemia, aplastic anemia, pure red cell anemia and

idiopathic thrombocytopenia), systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), irritable bowel syndrome, celiac disease, periodontitis, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, multiple sclerosis, endocrine ophthalmopathy, Grave's disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, primary biliary cirrhosis, anterior uveitis, posterior uveitis, Sjogren's syndrome, interstitial lung fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, nephritis, vasculitis, diverticulitis, interstitial cystitis, glomerulonephritis, (e.g., including idiopathic nephrotic syndrome, or minimal change nephropathy), chronic granulomatous disease, endometriosis, leptospirosis renal disease, glaucoma, retinal disease, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscle wasting, catabolic disorders, obesity, fetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, mesothelioma, anhidrotic ectodermal dysplasia, Behcet's disease, incontinentia pigmenti, Paget's disease, pancreatitis, hereditary periodic fever syndrome, asthma, acute lung injury, acute respiratory distress syndrome, eosinophilia, hypersensitivities, anaphylaxis, fibrositis, gastritis, gastroenteritis, nasal sinusitis, silica induced diseases, chronic obstructive pulmonary disease (COPD), cystic fibrosis, acid-induced lung injury, pulmonary hypertension, polyneuropathy, cataracts, muscle inflammation in conjunction with systemic sclerosis, inclusion body myositis, thyroiditis, Addison's disease, lichen planus, appendicitis, atopic dermatitis, allergy, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, colitis, cystitis, dacryoadenitis, dermatitis, juvenile rheumatoid arthritis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, Henoch-Schonlein purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, oophoritis, orchitis, osteitis, otitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, vulvitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, pemphigus vulgaris, pemphigus

foliaceus, paraneoplastic pemphigus, epidermolysis bullosa acquisita, acute gout, chronic gout, chronic gouty arthritis, psoriasis, psoriatic arthritis, Cryopyrin Associated Periodic Syndrome (CAPS) and osteoarthritis.

31. Use of a compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt or a stereoisomer thereof, in the manufacture of a medicament for the treatment of a cancer, an inflammatory disorder, an autoimmune disease, a metabolic disorder, a hereditary disorder, a hormone-related disease, immunodeficiency disorders, a condition associated with cell death, a destructive bone disorder, thrombin-induced platelet aggregation, liver disease and a cardiovascular disorder.

32. The use of claim 31, wherein the cancer is selected from a solid tumor, benign or malignant tumor; carcinoma of the brain, kidney, liver, stomach, vagina, ovaries, gastric tumors, breast, bladder, colon, prostate, pancreas, lung, cervix, testis, skin, bone or thyroid; sarcoma, glioblastoma, neuroblastoma, gastrointestinal cancer, a tumor of the neck and head, an epidermal hyperproliferation, prostate hyperplasia, a neoplasia, adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, non-small-cell lung carcinoma, lymphomas, Hodgkins and Non-Hodgkins lymphoma, a mammary carcinoma, follicular carcinoma, papillary carcinoma, seminoma, melanoma, haematological malignancies, leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), activated B-cell-like DLBCL, chronic lymphocytic leukemia (CLL), chronic lymphocytic lymphoma, primary effusion lymphoma, Burkitt lymphoma, Burkitt leukemia, acute lymphocytic leukemia, B-cell pro lymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's macroglobulinemia (WM), splenic marginal zone lymphoma, intravascular large B-cell lymphoma, plasmacytoma and multiple myeloma.

33. The compound for use of claim 31, wherein the inflammatory disorder is selected from ocular allergy, conjunctivitis, keratoconjunctivitis sicca, vernal conjunctivitis, allergic rhinitis, autoimmune hematological disorders hemolytic anemia, aplastic anemia, pure red cell anemia and idiopathic thrombocytopenia, systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis,

myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome, celiac disease, periodontitis, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, multiple sclerosis, endocrine ophthalmopathy, Grave's disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, primary biliary cirrhosis, anterior uveitis, posterior uveitis, Sjogren's syndrome, interstitial lung fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, nephritis, vasculitis, diverticulitis, interstitial cystitis, glomerulonephritis, idiopathic nephrotic syndrome, minimal change nephropathy, chronic granulomatous disease, endometriosis, leptospirosis renal disease, glaucoma, retinal disease, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscle wasting, catabolic disorders, obesity, fetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, mesothelioma, anhidrotic ectodermal dysplasia, Behcet's disease, incontinentia pigmenti, Paget's disease, pancreatitis, hereditary periodic fever syndrome, asthma, acute lung injury, acute respiratory distress syndrome, eosinophilia, hypersensitivities, anaphylaxis, fibrositis, gastritis, gastroenteritis, nasal sinusitis, silica induced diseases, chronic obstructive pulmonary disease (COPD), cystic fibrosis, acid-induced lung injury, pulmonary hypertension, polyneuropathy, cataracts, muscle inflammation in conjunction with systemic sclerosis, inclusion body myositis, thyroiditis, Addison's disease, lichen planus, appendicitis, atopic dermatitis, allergy, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, colitis, cystitis, dacryoadenitis, dermatitis, juvenile rheumatoid arthritis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, Henoch-Schonlein purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, oophoritis, orchitis, osteitis, otitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, ulcerative colitis, vasculitis, vulvitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, epidermolysis bullosa acquisita, acute gout, chronic gout, chronic gouty arthritis, psoriasis, psoriatic arthritis, Cryopyrin Associated Periodic Syndrome (CAPS) and osteoarthritis.